registration study – on track to report in the third quarter, according to John F. Crowley, chairman and CEO of Amicus

Earlier this month, Gilead disclosed earlier data from ELECTRON showing that 100 percent of patients in two cohorts – treatment-naïve and null responders – achieved rapid viral response at four weeks. (See BioWorld Today, Feb. 6, 2012.) "Maybe we were a little more enthusiastic than we should have been," said John F. Milligan, Gilead's chief operating officer

Gilead's HCV Math John F. Milligan, president and chief operating officer of Gilead Sciences Inc., walked the audience for his BIO CEO fireside chat through the math of hepatitis C virus (HCV) that led the HIV-focused company to buy Pharmasett Inc

Cerenis Therapeutics, of Toulouse, France, appointed John F. Paolini chief medical officer and named Richard C. Pasternak to its board

Amicus Therapeutics Inc., of Cranbury, N.J., said John F. Crowley will transition from chairman and CEO to executive chairman

John F. Crowley7 425 167 592 1,707 1,672 3,971 400 6.3 539 0 7.98 658.7 250.7 15 AMYLIN PHARMACEUTICALS Daniel M. Bradbury8 656 0 656 40 3,801 4,496 559 17.3 0 23 10.85 1,800.50 1,989.00 840.1 ANESIVA Michael L. Kranda9 449 175 624 63 63 750 0 0 0 0 0.35 0 7.7 0.3 ANTIGENICS /DE Garo H. Armen

John F. Crowley AMICUS THERAPEUTICS INC 425 167 592 108 Samuel E. Lynch BIOMIMETIC THERAPEUTICS INC 450 134 584 109 Simon Pedder CHELSEA THERAPEUTICS INTL 389 193 582 110 Steven R. Deitcher HANA BIOSCIENCES INC 420 150 570 111 Howard C. Birndorf NANOGEN INC 520 47 567 112 Douglas A. Michels ORASURE TECHNOLOGIES INC 475 88 563 113 Thomas A. Bologna ORCHID CELLMARK INC 560 0 560 114 Arthur T. Sands LEXICON PHARMACEUTICALS INC 558 0 558 115 Keith A

For the 92 chief operating officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Michael Walsh CYPRESS BIOSCIENCE INC 300 1,747 2,047 2 Jerry E. Corbin INTEGRA LIFESCIENCES HLDGS 227 1,572 1,799 3 Gordon G. Pugh ALKERMES INC 353 1,080 1,434 4 Yakov Kogan CLEVELAND BIOLABS INC 218 1,100 1,318 5 John F. Milligan GILEAD SCIENCES INC 728 442 1,170 6 Marc S. Hanover GTX INC 435 694

John F. Milligan13 728 442 1170 8 841 2018 10796 666 GTX Marc S. Hanover 435 694 1129 21 3745 4894 HEMISPHERX BIOPHARMA Wayne Springate14 150 27 177 6 538 721 HUMAN GENOME SCIENCES Barry A. Labinger 475 424 899 334 4076 5309 131 ILLUMINA Tristan B. Orpin 351 351 116 467 3248 INOVIO BIOMEDICAL Punit Dhillon 172 0 172 261 180 613 390 INSPIRE PHARMA Joseph K. Schachle 311 165 476 27 458 960 16 INTEGRA LIFESCIENCES Gerard S

John F. Weidenbruch IDENIX PHARMACEUTICALS INC 323 130 453 20 Matthew M. Gosling DEPOMED INC 325 124 449 21 Jennifer Evans Stacey AUXILIUM PHARMA INC 317 132 448 22 Richard F. Hamm Jr

John F. Weidenbruch5 323 118 441 11 137 589 0 0 IDEXX LABS Conan R. Deady6 280 0 280 1 234 515 1,092 38 ILLUMINA Christian G. Cabou 336 112 448 7 338 794 4,031 0 IMMUCOR Philip H. Moise 450 0 450 10 962 1,422 0 0 INCYTE CORP Patricia A. Schreck 279 114 393 3 215 612 0 0 INSPIRE PHARMA Joseph M. Spagnardi 272 131 403 0 249 652 0 16 INTEGRA LIFESCIENCES Judith E. O'Grady 243 0 243 1 99 343 339 0 ISTA PHARMA Marvin J. Garrett

Vermillion Inc., of Fremont, Calif., said that the U.S. Bankruptcy Court for the District of Delaware issued an order April 14 approving a management incentive plan for three directors of the board: Gail S. Page, James S. Burns and John F. Hamilton

John F. Crowley AMICUS THERAPEUTICS 425 167 1,707 539 2,838 John L. Bishop CEPHEID 488 0 43 11,614 12,145 John M. Maraganore ALNYLAM PHARMACEUTICALS 525 0 8 2,623 3,156 Jonathan W. Ayers IDEXX LABS 700 675 13 125 1,513 Joshua S. Boger VERTEX PHARMACEUTICALS 709 979 12 2,758 4,457 Kathy Ordo ez CELERA CORP 650 338 3 364 1,355 Kevin W. Sharer AMGEN 1,562 3,875 531 3,686 9,653 Leonard Bell ALEXION PHARMACEUTICALS 623 750 9 2,881 4,263 Leonard

Amicus Therapeutics Inc., of Cranbury, N.J., elected John F. Crowley chairman

plc, of Dublin, Ireland, appointed John F. Thero chief financial officer

Staff Writer Amicus Therapeutics Inc.'s bad preliminary news with Plicera from a small Phase II study in Gaucher disease "does advance the general proof of concept of chaperones" despite the failure, CEO John F. Crowley told investors during an aftermarket conference call Friday

A few probably were surprised that Amigal - shooting for the same surrogate endpoint as Fabrazyme - made it to Phase III at all, said John F. Crowley, president and CEO of Amicus

We knew it would be a push" to persuade the FDA that a comparison trial with Fabrazyme - which sold $494 million last year, up 14 percent from 2007 - is not necessary, said John F. Crowley, president and CEO of Amicus

John F. Womelsdorf CYCLACEL PHARMACEUTICALS 254 41 295 57 William C. Kruka CALIPER LIFE SCIENCES INC 242 48 290 58 William J. Welch MONOGRAM BIOSCIENCES INC# 282 - 282 59 David A. Socks CADENCE PHARMACEUTICALS INC 225 55 280 60 Yakov Kogan CLEVELAND BIOLABS INC 180 97 277 61 Kevin P. Poulos OPTIMER PHARMA INC 182 93 275 62 Meghan Fitzgerald VION PHARMACEUTICALS INC 247 26 274 63 Louis Ploth Jr